{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:46:07Z","timestamp":1767008767462,"version":"3.48.0"},"reference-count":31,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017531","name":"Medical and Health Research Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY1271"],"award-info":[{"award-number":["2022KY1271"]}],"id":[{"id":"10.13039\/501100017531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,6,24]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Non-cystic fibrosis bronchiectasis (NCFB) brought a heavy healthcare burden worldwide. Macrolide maintenance therapy was proved to be helpful in reducing exacerbation of NCFB. However, the optimal dosing regimens of macrolides have not been determined, and its efficacy in Chinese NCFB population has not been validated. This protocol describes a head-to-head clinical trial designed to compare the efficacy of two dosing regimens of azithromycin in Chinese NCFB population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This prospective, open-label and randomised controlled trial will be conducted in the First People\u2019s Hospital of Jiashan, China. Eligible patients with high-resolution CT defined NCFB will be randomly divided into three groups, which will receive either 250\u2009mg daily azithromycin, or 500\u2009mg three-times-weekly azithromycin or no treatment for 6 months. They will be followed up for another 6 months without treatment. The primary outcome is the mean rate of protocol-defined pulmonary exacerbation at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from the First People\u2019s Hospital of Jiashan Ethics Committee. The findings will be disseminated in peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2100052906.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-059186","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T10:39:22Z","timestamp":1657276762000},"page":"e059186","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Daily versus three-times-weekly azithromycin in Chinese patients with non-cystic fibrosis bronchiectasis: protocol for a prospective, open-label and randomised controlled trial"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-3383","authenticated-orcid":false,"given":"Yanxiong","family":"Mao","sequence":"first","affiliation":[{"name":"Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihao","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"You","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjiang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First People\u2019s Hospital of Jiashan, Jiashan, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"2025121223164998000_12.7.e059186.1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","article-title":"Bronchiectasis","volume":"4","author":"Chalmers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025121223164998000_12.7.e059186.2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.chest.2018.10.027","article-title":"Bronchiectasis","volume":"155","author":"McShane","year":"2019","journal-title":"Chest"},{"key":"2025121223164998000_12.7.e059186.3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105940","article-title":"Non-CF bronchiectasis: orphan disease no longer","volume":"166","author":"Imam","year":"2020","journal-title":"Respir Med"},{"key":"2025121223164998000_12.7.e059186.4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2209"},{"key":"2025121223164998000_12.7.e059186.5","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0055-2019","article-title":"The biology of pulmonary exacerbations in bronchiectasis","volume":"28","author":"Amati","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2025121223164998000_12.7.e059186.6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-Term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025121223164998000_12.7.e059186.7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061190","article-title":"Exacerbations and changes in physical activity and sedentary behaviour in patients with bronchiectasis after 1 year","volume":"10","author":"Alcaraz-Serrano","year":"2021","journal-title":"J Clin Med"},{"key":"2025121223164998000_12.7.e059186.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0099"},{"key":"2025121223164998000_12.7.e059186.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-86407-8","article-title":"Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities","volume":"11","author":"Choi","year":"2021","journal-title":"Sci Rep"},{"key":"2025121223164998000_12.7.e059186.10","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/resp.13828","article-title":"Cost of hospitalization for bronchiectasis exacerbation in children","volume":"25","author":"Goyal","year":"2020","journal-title":"Respirology"},{"key":"2025121223164998000_12.7.e059186.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02990-2020"},{"key":"2025121223164998000_12.7.e059186.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QCO.0000000000000628","article-title":"Managing and preventing exacerbation of bronchiectasis","volume":"33","author":"Abo-Leyah","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2025121223164998000_12.7.e059186.13","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.160830"},{"key":"2025121223164998000_12.7.e059186.14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/17476348.2016.1258304","article-title":"Long-Term antibiotic treatment for non-cystic fibrosis bronchiectasis in adults: evidence, current practice and future use","volume":"10","author":"Goldman","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"2025121223164998000_12.7.e059186.15","doi-asserted-by":"crossref","DOI":"10.1177\/1479972318790269","article-title":"Azithromycin or erythromycin? macrolides for non-cystic fibrosis bronchiectasis in adults: a systematic review and adjusted indirect treatment comparison","volume":"16","author":"Li","year":"2019","journal-title":"Chron Respir Dis"},{"key":"2025121223164998000_12.7.e059186.16","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/resp.12375","article-title":"Efficacy of azithromycin in the treatment of bronchiectasis","volume":"19","author":"Lourdesamy Anthony","year":"2014","journal-title":"Respirology"},{"key":"2025121223164998000_12.7.e059186.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1937"},{"key":"2025121223164998000_12.7.e059186.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2290"},{"key":"2025121223164998000_12.7.e059186.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60953-2"},{"key":"2025121223164998000_12.7.e059186.20","first-page":"Cd012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121223164998000_12.7.e059186.21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"key":"2025121223164998000_12.7.e059186.22","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212468"},{"key":"2025121223164998000_12.7.e059186.23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5694\/mja17.01195","article-title":"Management of bronchiectasis in adults","volume":"209","author":"Visser","year":"2018","journal-title":"Med J Aust"},{"key":"2025121223164998000_12.7.e059186.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.08.1451"},{"key":"2025121223164998000_12.7.e059186.25","first-page":"867","article-title":"Advantages and drawbacks of long-term macrolide use in the treatment of non-cystic fibrosis bronchiectasis","volume":"6","author":"Fan","year":"2014","journal-title":"J Thorac Dis"},{"key":"2025121223164998000_12.7.e059186.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01888-2015"},{"key":"2025121223164998000_12.7.e059186.27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-2600(18)30053-5","article-title":"Bronchiectasis: new therapies and new perspectives","volume":"6","author":"Chalmers","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025121223164998000_12.7.e059186.28","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0209-3"},{"key":"2025121223164998000_12.7.e059186.29","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.117703"},{"key":"2025121223164998000_12.7.e059186.30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"Eur Respir J"},{"key":"2025121223164998000_12.7.e059186.31","doi-asserted-by":"publisher","DOI":"10.4055\/cios.2014.6.1.103"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-059186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:16:59Z","timestamp":1765610219000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-059186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,8]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bmjopen-2021-059186"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-059186","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}